Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of 5-Azacitidine Plus PD-1/PD-L1 Inhibitor in Patients With PD-1/PD-L1 Refractory Tumors

NCT07404332 is registered in ClinicalTrials.gov with Mohammed Milhem as lead sponsor.

NCT NCT07404332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of 5-Azacitidine Plus PD-1/PD-L1 Inhibitor in Patients With PD-1/PD-L1 Refractory Tumors
Lead sponsor
Mohammed Milhem
Phase
Phase 1
Overall status
Recruiting
Start date
February 11, 2026
Completion date
February 28, 2031
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic tumor, solid tumor